The apparent mineralocorticoid excess syndrome (AME) is a rare autosomal recessive disorder due to the deficiency of 11β-hydroxysteroid dehydrogenase type 2 enzyme (11beta-HSD2). The 11beta-HSD2 enzyme, encoded by HSD11B2 gene, metabolizes active Cortisol in cortisone. Mutations on HSD11B2 gene affect the enzyme activity by leading to an excess of Cortisol, which causes its inappropriate access to mineralocorticoid receptor. Therefore, Cortisol will bind mineralocorticoid receptor. The human HSD11B2 gene maps to chromosome 16q22 and consists of five exons encoding a protein of 405 amino acids. We present here clinical and molecular studies on a Brazilian boy who was born pre-term after an oligodramnious pregnancy. He was diagnosed as having AME at the age of 26 months. His parents are second cousins. Molecular characterization of the HSD11B2 gene revealed the homozygous mutation p.R186C. The patient described here is the second case of HDS11B2 gene mutation reported in Brazilian patients with AME.52812771281White, P.C., Mune, T., Agarwal, A.K., 11beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess (1997) Endocr Rev, 18 (1), pp. 135-156New, M.I., Wilson, R.C., Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess (1999) Proc Natl Acad Sci USA, 96 (22), pp. 12790-12797Luft, F.C., Mendelian forms of human hypertension and mechanisms of disease (2003) Clin Med Res, 1 (4), pp. 291-300Krozowski, Z., The 11beta-hydroxysteroid dehydrogenases: Functions and physiological effects (1999) Mol Cell Endocrinol, 151 (1-2), pp. 121-127Krozowski, Z.S., Funder, J.W., Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity (1983) Proc Natl Acad Sci USA, 80 (19), pp. 6056-6060Edwards, C., Stewart, P., Burt, D., Brett, L., Mclntyre, M., Sutanto, W., Localisation of 11b-hydroxysteroid dehydrogenase: Tissue specific protector of the mineralocorticoid receptor (1988) Lancet, 2 (8618), pp. 986-989Krozowski, Z.S., Provencher, P.H., Smith, R.E., Obeyesekere, V.R., Mercer, W.R., Albiston, A.L., Isozymes of 11 beta-hydroxysteroid dehydrogenase: Which enzyme endows mineralocorticoid specificity? (1994) Steroids, 59 (2), pp. 116-120Moore, C.C., Mellon, S.H., Murai, J., Siiteri, P.K., Miller, W.L., Structure and function of the hepatic form of 11b-hydroxysteroid dehydrogenase in the squirrel monkey, an animal model of glucocorticoid resistance (1993) Endocrinology, 133 (1), pp. 368-375Stewart, P.M., Murry, B.A., Mason, J., Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform (1994) J Clin Endocrinol Metab, 79 (2), pp. 480-484Rusvai, E., Naray-Fejes-Toth, A., A new isoform of 11b-hydroxysteroid dehydrogenase in aldosterone target cells (1993) J Biol Chem, 268 (15), pp. 10717-10720Agarwal AK, Rogerson FM, Mune T, White PC. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics. 1995;29f1): 195-9Mune, T., Rogerson, F.M., Nikkilä, H., Agarwal, A.K., White, P.C., Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase (1995) Nat Genet, 10 (4), pp. 394-399Li, A., Tedde, R., Krozowski, Z.S., Pala, A., Li, K.X., Shackleton, C.H., Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess (1998) Am J Hum Genet, 63 (2), pp. 370-379New, M., Geller, D.S., Fallo, F., Wilson, R.C., Monogenic low renin hypertension (2005) Trends Endocrinol Metab, 16 (3), pp. 92-97Stewart, P.M., Krozowski, Z.S., Gupta, A., Milford, D.V., Howie, A.J., Sheppard, M.C., Whorwood, C.B., Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene (1996) Lancet, 347 (8994), pp. 88-91Dave-Sharma, S., Wilson, R.C., Harbison, M.D., Newfield, R., Azar, M.R., Krozowski, Z.S., Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess (1998) J Clin Endocrin Metab, 83 (7), pp. 2244-2254Ugrasbul, F., Wiens, T., Rubinstein, P., New, M., Wilson, R.C., Prevalence of mild apparent mineralocorticoid excess in Mennonites (1999) J Clin Endocrinol Metab, 84 (12), pp. 4735-4738Wilson, R.C., Dave-Sharma, S., Wei, J.Q., Obeyesekere, V.R., Li, K., Ferrari, P., A genetic defect resulting in mild low-renin hypertension (1998) Proc Natl Acad Sci USA, 95 (17), pp. 10200-10205Lavery, G.G., Ronconi, V., Draper, N., Rabbitt, E.H., Lyons, V., Chapman, K.E., Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene (2003) Hypertension, 42 (2), pp. 123-129Inada, M., Iwasaki, K., Imai, C., Hashimoto, S., Two elderly patients with mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) impairment (2008) Intern Med, 47 (7), pp. 631-636Nunez, B.S., Rogerson, F.M., Mune, T., Igarashi, Y., Nakagawa, Y., Phillipov, G., Mutants of 11 beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: Improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess (1999) Hypertension, 34 (4 PART 1), pp. 638-642Sambrook, J., Fristsch, E.F., Maniatis, T.E., (1989) Molecular Cloning: A Laboratory Manual, , Cold Spring Harbor Press, Cold Spring Harbor, NY, USAWilson, R.C., Harbison, M.D., Krozowski, Z.S., Funder, J.W., Shackleton, C.H., Hanauske-Abel, H.M., Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess (1995) J Clin Endocrinol Metab, 80 (11), pp. 3145-3150Ferrari, P., Obeyesekere, V.R., Li, K., Wilson, R.C., New, M., Funder, J.W., Krozowski, Z.S., Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess (1996) Mol Cell Endocrinol, 119 (1), pp. 21-24Wilson, R.C., Nimkarn, S., New, M., Apparent mineralocorticoid excess (2001) Trends Endocrinol Metab, 12 (3), pp. 104-111Quinkler, M., Bappal, B., Draper, N., Atterbury, A.J., Lavery, G.G., Walker, E.A., Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population (2004) Mol Cell Endocrinol, 217 (1-2), pp. 143-149Kamide, K., Kokubo, Y., Hanada, H., Nagura, J., Yang, J., Takiuchi, S., Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations (2006) Hypertens Res, 29 (4), pp. 243-252Morineau, G., Sulmont, V., Salomon, R., Fiquet-Kempf, B., Jeunamaitre, X., Nicod, J., Ferrari, P., Apparent mineralocorticoid excess: Report of six new cases and extensive personal experience (2006) J Am Soc Nephrol, 17 (11), pp. 3176-3184Parra, F.C., Amado, R.C., Lambertucci, J.R., Rocha, J., Antunes, C.M., Pena, S.D., Color and genomic ancestry in Brazilians (2003) Proc Natl Acad Sci USA, 100 (1), pp. 177-182Ollila, J., Lappalainen, I., Vihinen, M., Sequence specificity in CpG mutation hotspots (1996) FEBS Lett, 396 (2-3), pp. 119-122el Antri, S., Mauffret, O., Monnot, M., Lescot, E., Convert, O., Fermandjian, S., Structural deviations at CpG provide a plausible explanation for the high frequency of mutation at this site. Phosphorus nuclear magnetic resonance and circular dichroism studies (1993) J Mol Biol, 230 (2), pp. 373-378Rogoff, D., Smolenicka, Z., Bergadá, I., Vallejo, G., Barontini, M., Heinrich, J.J., Ferrari, P., The codon 213 of the 11 beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess (1998) J Clin Endocrinol Metab, 83 (12), pp. 4391-4393Li, A., Li, K.X., Marui, S., Krozowski, Z.S., Batista, M.C., Whorwood, C.B., Apparent mineralocorticoid excess in a Brazilian kindred: Hypertension in the heterozygote state (1997) J Hypertens, 15 (12 PART 1), pp. 1397-1402